Aptose Biosciences 2017 Cowen Health Care Conference

Aptose Biosciences presented pipeline updates focused on CG'806, a first-in-class pan-FLT3/BTK kinase inhibitor for treating acute myeloid leukemia and ibrutnib-resistant lymphomas. The company highlighted strategic reprioritization toward CG'806 alongside earlier-stage programs APTO-253 and BRD4 inhibitors for hematologic cancers.